Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial

BACKGROUND AND OBJECTIVES: Impaired nitric oxide signaling through soluble guanylate cyclase has been implicated in the pathophysiology of diabetic kidney disease. Praliciguat, a soluble guanylate cyclase stimulator that amplifies nitric oxide signaling, inhibited kidney inflammation and fibrosis in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin J Am Soc Nephrol
Autori principali: Hanrahan, John P., de Boer, Ian H., Bakris, George L., Wilson, Phebe J., Wakefield, James D., Seferovic, Jelena P., Chickering, Jennifer G., Chien, Yueh-tyng, Carlson, Kenneth, Cressman, Michael D., Currie, Mark G., Milne, G. Todd, Profy, Albert T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Nephrology 2021
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7792638/
https://ncbi.nlm.nih.gov/pubmed/33328269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08410520
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi